Table 2. Amino acid substitutions and frequency of blood donors with mutations conferring resistance to protease inhibitors.
| Sample no | Subtype | Mutation | Resistance |
| 6 | 1a | V55A | Boceprevir/Telaprevir |
| 32 | 1a | R155K | Boceprevir/Telaprevir/Simeprevir |
| 33 | 1b | R117H | Boceprevir/Telaprevir |
| 44 | 1a | R155K | Boceprevir/Telaprevir/Simeprevir |
| 54 | 1b | D168G | Boceprevir |
| 55 | 1a | V36L/V55A | Boceprevir/Telaprevir |
| 62 | 1a | R155K | Boceprevir/Telaprevir/Simeprevir |
| 63 | 1b | T54S | Telaprevir/Simeprevir |
| 64 | 1a | Q80L | Low Simeprevir |
| 70 | 1b | R117H | Boceprevir/Telaprevir |
| 93 | 1a | R155K | Boceprevir/Telaprevir/Simeprevir |
| 107 | 1a | V55A | Boceprevir/Telaprevir |
| 110 | 1a | V36L | Boceprevir/Telaprevir |
| 127 | 1b | V55A | Boceprevir/Telaprevir |
| 134 | 1b | T54S | Telaprevir/Simeprevir |
| 184 | 1a | R155K | Boceprevir/Telaprevir/Simeprevir |
| Totalfrequency | 16/125 (12.8%) | ||
| Boceprevir | 13/125 (10.4%) | ||
| Telaprevir | 14/125 (11.2%) | ||
| Simeprevir | 8/125 (6.4%) |